Nanocarriers for Treatment of Ocular Neovascularization in the Back of the Eye: New Vehicles for Ophthalmic Drug Delivery

References

• Chen J , SmithLE . Retinopathy of prematurity . Angiogenesis10 ( 2 ), 133 – 140 ( 2007 ).
   PubMedGoogle Scholar
• Adamis AP , AielloLP , D’amatoRA . Angiogenesis and ophthalmic disease . Angiogenesis3 ( 1 ), 9 – 14 ( 1999 ).
   PubMedGoogle Scholar
• Kompella UB , AmriteAC , Pacha RaviR , DurazoSA . Nanomedicines for back of the eye drug delivery, gene delivery, and imaging . Prog. Retin. Eye Res.36 , 172 – 198 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wadhwa S , PaliwalR , PaliwalSR , VyasSP . Nanocarriers in ocular drug delivery: an update review . Curr. Pharm. Des.15 ( 23 ), 2724 – 2750 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Hughes PM , OlejnikO , Chang-LinJE , WilsonCG . Topical and systemic drug delivery to the posterior segments . Adv. Drug Deliv. Rev.57 ( 14 ), 2010 – 2032 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Gopinath B , BaurLA , WangJJet al. Smaller birth size is associated with narrower retinal arterioles in early adolescence . Microcirculation17 ( 8 ), 660 – 668 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Truong A , WongTY , KhachigianLM . Emerging therapeutic approaches in the management of retinal angiogenesis and edema . J. Mol. Med. (Berl.)89 ( 4 ), 343 – 361 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Campochiaro PA . Ocular neovascularization . J. Mol. Med. (Berl.)91 ( 3 ), 311 – 321 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Cheung N , MitchellP , WongTY . Diabetic retinopathy . Lancet376 ( 9735 ), 124 – 136 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Sato T , KusakaS , ShimojoH , FujikadoT . Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity . Ophthalmology116 ( 9 ), 1599 – 1603 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Miller JW , Le CouterJ , StraussEC , FerraraN . Vascular endothelial growth factor A in intraocular vascular disease . Ophthalmology120 ( 1 ), 106 – 114 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Curcio CA , JohnsonM . Structure, function, and pathology of bruch’s membrane . Elastic146 ( 152 ), 210 – 213 ( 2012 ).
   Google Scholar
• Cheung CM , WongTY . Treatment of age-related macular degeneration . Lancet382 ( 9900 ), 1230 – 1232 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wong TY , Ohno-MatsuiK , LevezielNet al. Myopic choroidal neovascularisation: current concepts and update on clinical management . Br. J. Ophthalmol. 99(3), 289–296 ( 2014 ).
   Web of Science ®Google Scholar
• Thakur SS , BarnettNL , DonaldsonMJ , ParekhHS . Intravitreal drug delivery in retinal disease: are we out of our depth?Expert Opin. Drug Deliv.11 ( 10 ), 1575 – 1590 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wang X , SawadaT , KakinokiMet al. Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration . Graefes Arch. Clin. Exp. Ophthalmol.252 ( 7 ), 1033 – 1039 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Avery RL , CastellarinAA , SteinleNCet al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD . Br. J. Ophthalmol.98 ( 12 ), 1636 – 1641 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U , EldemB , GuymerRet al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study . Ophthalmology118 ( 5 ), 831 – 839 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Zhang X , ZengH , BaoS , WangN , GilliesMC . Diabetic macular edema: new concepts in patho-physiology and treatment . Cell Biosci.4 , 27 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Israelachvili JN , MitchellDJ , NinhamBW . Theory of self-assembly of hydrocarbon amphiphiles into micelles and bilayers . J. Chem. Society-Faraday Transactions II72 , 1525 – 1568 ( 1976 ).
   Web of Science ®Google Scholar
• Tanford C . The Hydrophobic Effects: Formation Of Micelles And Biological Membranes . Wiley , NY, USA ( 1980 ).
   Google Scholar
• Yaghmur A , De CampoL , SagalowiczL , LeserME , GlatterO . Emulsified microemulsions and oil-containing liquid crystalline phases . Langmuir21 ( 2 ), 569 – 577 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Sagalowicz L , LeserME , WatzkeHJ , MichelM . Monoglyceride self-assembly structures as delivery vehicles . Trends Food Sci. Technol.17 ( 5 ), 204 – 214 ( 2006 ).
   Web of Science ®Google Scholar
• Konopka K , LimaMCPD , SimõesS , RossiJJ , DüzgünesN . Delivery of novel macromolecular drugs against HIV-1 . Expert Opin. Biol. Ther.1 ( 6 ), 949 – 970 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Hamilton A , BiganzoliL , ColemanRet al. EORTC 10968: a Phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer . Ann. Oncol.13 ( 6 ), 910 – 918 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Grayson LS , HansbroughJF , Zapata-SirventRL , KimT , KimS . Pharmacokinetics of DepoFoam gentamicin delivery system and effect on soft tissue infection . J. Surg. Res.55 ( 5 ), 559 – 564 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Allen TM , CullisPR . Liposomal drug delivery systems: from concept to clinical applications . Adv. Drug Deliv. Rev.65 ( 1 ), 36 – 48 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Rajala A , WangY , ZhuYet al. Nanoparticle-assisted targeted delivery of eye-specific genes to eyes significantly improves the vision of blind mice in vivo . Nano Lett.14 ( 9 ), 5257 – 5263 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Li X , ZhangZ , LiJ , SunS , WengY , ChenH . Diclofenac/biodegradable polymer micelles for ocular applications . Nanoscale4 ( 15 ), 4667 – 4673 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Yang H , TyagiP , KadamRS , HoldenCA , KompellaUB . Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration . ACS Nano6 ( 9 ), 7595 – 7606 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Connor EE , MwamukaJ , GoleA , MurphyCJ , WyattMD . Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity . Small1 ( 3 ), 325 – 327 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Skirtach AG , JavierAM , KreftOet al. Laser-induced release of encapsulated materials inside living cells . Angew. Chem. Int. Ed. Engl.45 ( 28 ), 4612 – 4617 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kim JH , KimJH , KimKW , KimMH , YuYS . Intravenously administered gold nanoparticles pass through the blood–retinal barrier depending on the particle size, and induce no retinal toxicity . Nanotechnology20 ( 50 ), 505101 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ahamed M . Silica nanoparticles-induced cytotoxicity, oxidative stress and apoptosis in cultured A431 and A549 cells . Human Exp. Toxicol.32 ( 2 ), 186 – 195 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Vivero-Escoto JL , SlowingIi , TrewynBG , LinVSY . Mesoporous silica nanoparticles for intracellular controlled drug delivery . Small6 ( 18 ), 1952 – 1967 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Slowing Ii , Vivero-EscotoJL , WuCW , LinVSY . Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers . Adv. Drug Deliv. Rev.60 ( 11 ), 1278 – 1288 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Carpenter EE . Iron nanoparticles as potential magnetic carriers . J. Magn. Magnet. Mater.225 ( 1 ), 17 – 20 ( 2001 ).
   Web of Science ®Google Scholar
• Häfeli U . Magnetically modulated therapeutic systems . Int. J. Pharmaceut.277 ( 1 ), 19 – 24 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Pankhurst QA , ConnollyJ , JonesS , DobsonJ . Applications of magnetic nanoparticles in biomedicine . J. Phys. D Appl. Phys.36 ( 13 ), R167 ( 2003 ).
   Web of Science ®Google Scholar
• Yanai A , HafeliUO , MetcalfeALet al. Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles . Cell Transplant.21 ( 6 ), 1137 – 1148 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Yasukawa T , OguraY , KimuraH , SakuraiE , TabataY . Drug delivery from ocular implants . Expert Opin. Drug Deliv.3 ( 2 ), 261 – 273 ( 2006 ).
   PubMedGoogle Scholar
• Hsu J . Drug delivery methods for posterior segment disease . Curr. Opin. Ophthalmol.18 ( 3 ), 235 – 239 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Lee VH , RobinsonJR . Topical ocular drug delivery: recent developments and future challenges . J. Ocul. Pharmacol.2 ( 1 ), 67 – 108 ( 1986 ).
   PubMedGoogle Scholar
• Maurice DM . Drug delivery to the posterior segment from drops . Surv. Ophthalmol.47 ( Suppl. 1 ), S41 – S52 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Gan L , WangJ , JiangMet al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers . Drug Discov. Today18 ( 5–6 ), 290 – 297 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J , BernardesR , LoboC . Blood–retinal barrier . Eur. J. Ophthalmol.21 ( Suppl. 6 ), S3 – S9 ( 2011 ).
   PubMedGoogle Scholar
• Singh SR , GrossniklausHE , KangSJ , EdelhauserHF , AmbatiBK , KompellaUB . Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV . Gene Ther.16 ( 5 ), 645 – 659 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ladas ID , KaragiannisDA , RouvasAA , KotsolisAI , LiotsouA , VergadosI . Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections . Retina29 ( 3 ), 313 – 318 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Young S , LarkinG , BranleyM , LightmanS . Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis . Clin. Experiment. Ophthalmol.29 ( 1 ), 2 – 6 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Bourges JL , GautierSE , DelieFet al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles . Invest. Ophthalmol. Vis. Sci.44 ( 8 ), 3562 – 3569 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Shelke NB , KadamR , TyagiP , RaoVR , KompellaUB . Intravitreal poly(L-lactide) microparticles sustain retinal and choroidal delivery of TG-0054, a hydrophilic drug intended for neovascular diseases . Drug Deliv. Transl. Res.1 ( 1 ), 76 – 90 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Raghava S , HammondM , KompellaUB . Periocular routes for retinal drug delivery . Expert Opin. Drug Deliv.1 ( 1 ), 99 – 114 ( 2004 ).
   PubMedGoogle Scholar
• Lee TW , RobinsonJR . Drug delivery to the posterior segment of the eye III: the effect of parallel elimination pathway on the vitreous drug level after subconjunctival injection . J. Ocul. Pharmacol. Ther.20 ( 1 ), 55 – 64 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Amrite AC , KompellaUB . Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration . J. Pharm. Pharmacol.57 ( 12 ), 1555 – 1563 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Le Bourlais C , AcarL , ZiaH , SadoPA , NeedhamT , LevergeR . Ophthalmic drug delivery systems – recent advances . Prog. Retin. Eye Res.17 ( 1 ), 33 – 58 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Kim JH , KimMH , JoDH , YuYS , LeeTG , KimJH . The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation . Biomaterials32 ( 7 ), 1865 – 1871 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Cho WK , KangS , ChoiH , RhoCR . Topically administered gold nanoparticles inhibit experimental corneal neovascularization in mice . Cornea34 ( 4 ), 456 – 459 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kalishwaralal K , BanumathiE , Ram Kumar PandianSet al. Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells . Colloids Surf. B Biointerfaces73 ( 1 ), 51 – 57 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kalishwaralal K , BarathmanikanthS , PandianSR , DeepakV , GurunathanS . Silver nano – a trove for retinal therapies . J. Control. Release145 ( 2 ), 76 – 90 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Gurunathan S , LeeKJ , KalishwaralalK , SheikpranbabuS , VaidyanathanR , EomSH . Antiangiogenic properties of silver nanoparticles . Biomaterials30 ( 31 ), 6341 – 6350 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Jo DH , KimJH , YuYS , LeeTG , KimJH . Antiangiogenic effect of silicate nanoparticle on retinal neovascularization induced by vascular endothelial growth factor . Nanomedicine8 ( 5 ), 784 – 791 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gross N , RanjbarM , EversCet al. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes . Mol. Vis.19 , 54 – 61 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kim H , ChoiJS , KimKS , YangJA , JooCK , HahnSK . Flt1 peptide-hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of ocular neovascularization . Acta Biomaterialia8 ( 11 ), 3932 – 3940 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Park K , ChenY , HuYet al. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage . Diabetes58 ( 8 ), 1902 – 1913 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Iriyama A , ObaM , IshiiTet al. Gene transfer using micellar nanovectors inhibits choroidal neovascularization in vivo . PLoS ONE6 ( 12 ), e28560 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Di Tommaso C , BourgesJL , ValamaneshFet al. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies . Eur. J. Pharm. Biopharm.81 ( 2 ), 257 – 264 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Shmueli RB , OhnakaM , MikiAet al. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide . Biomaterials34 ( 30 ), 7544 – 7551 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Iwase T , FuJ , YoshidaTet al. Sustained delivery of a HIF-1 antagonist for ocular neovascularization . J. Control. Release172 ( 3 ), 625 – 633 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Xu J , WangY , LiYet al. Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model . J. Ocul. Pharmacol. Ther.23 ( 6 ), 527 – 540 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Luo L , ZhangX , HiranoYet al. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration . ACS Nano7 ( 4 ), 3264 – 3275 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wang Z , ChengR , LeeKet al. Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization . Arterioscler. Thromb. Vasc. Biol. 35(4), 855–864 ( 2015 ).
   Web of Science ®Google Scholar
• Lim LS , MitchellP , SeddonJM , HolzFG , WongTY . Age-related macular degeneration . Lancet379 ( 9827 ), 1728 – 1738 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Wong TY , ScottIU . Clinical practice. Retinal–vein occlusion . N. Engl. J. Med.363 ( 22 ), 2135 – 2144 ( 2010 ).
   PubMedGoogle Scholar
• Samad A , SultanaY , AqilM . Liposomal drug delivery systems: an update review . Curr. Drug Deliv.4 ( 4 ), 297 – 305 ( 2007 ).
   PubMedGoogle Scholar
• Wei L , CaiC , LinJ , ChenT . Dual-drug delivery system based on hydrogel/micelle composites . Biomaterials30 ( 13 ), 2606 – 2613 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kim S , ShiY , KimJY , ParkK , ChengJX . Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction . Expert Opin. Drug Deliv.7 ( 1 ), 49 – 62 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lin WS , HuangYW , ZhouXD , MaYF . In vitro toxicity of silica nanoparticles in human lung cancer cells . Toxicol. Appl. Pharmacol.217 ( 3 ), 252 – 259 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Lin YS , HaynesCL . Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity . J. Am. Chem. Soc.132 ( 13 ), 4834 – 4842 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Harris L , GoffJ , CarmichaelAet al. Magnetite nanoparticle dispersions stabilized with triblock copolymers . Chem. Mater.15 ( 6 ), 1367 – 1377 ( 2003 ).
   Web of Science ®Google Scholar
• Santra S , TapecR , TheodoropoulouN , DobsonJ , HebardA , TanW . Synthesis and characterization of silica-coated iron oxide nanoparticles in microemulsion: the effect of nonionic surfactants . Langmuir17 ( 10 ), 2900 – 2906 ( 2001 ).
   Web of Science ®Google Scholar
• Lee TW , RobinsonJR . Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection . J. Ocul. Pharmacol. Ther.20 ( 1 ), 43 – 53 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Lee TW , RobinsonJR . Drug delivery to the posterior segment of the eye: some insights on the penetration pathways after subconjunctival injection . J. Ocul. Pharmacol. Ther.17 ( 6 ), 565 – 572 ( 2001 ).
   PubMed Web of Science ®Google Scholar